DOCSLIB.ORG

Influence of Serum Amyloid a (SAA1) and SAA2 Gene Polymorphisms On

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Influence of Serum Amyloid a (SAA1) and SAA2 Gene Polymorphisms On Influence of Serum Amyloid A (SAA1) and SAA2 Gene Polymorphisms on Renal Amyloidosis, and on SAA/ C-Reactive Protein Values in Patients with Familial Mediterranean Fever in the Turkish Population AYSIN BAKKALOGLU, ALI DUZOVA, SEZA OZEN, BANU BALCI, NESRIN BESBAS, REZAN TOPALOGLU, FATIH OZALTIN, and ENGIN YILMAZ ABSTRACT. Objective. To evaluate the effect of serum amyloid A (SAA) 1 and SAA2 gene polymorphisms on SAA levels and renal amyloidosis in Turkish patients with familial Mediterranean fever (FMF). Methods. SAA1 and SAA2 gene polymorphisms and SAA levels were determined in 74 patients with FMF (39 female, 35 male; median age 11.5 yrs, range 1.0–23.0). All patients were on colchicine therapy. SAA1 and SAA2 gene polymorphisms were analyzed using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). SAA and C-reactive protein (CRP) values were measured and SAA/CRP values were calculated. Results. The median SAA level was 75 ng/ml (range 10.2–1500). SAA1 gene polymorphisms were: α/α genotype in 23 patients (31.1%), α/ß genotype in 30 patients (40.5%), α/γ genotype in one patient (1.4 %), ß/ß genotype in 14 patients (18.9%), ß/γ genotype in 5 patients (6.8 %), and γ/γ geno- type in one patient (1.4%). Of the 23 patients who had α/α genotype for the SAA1 polymorphism, 7 patients had developed renal amyloidosis (30.4%) compared to only one patient without this geno- type (1/51; 2.0%); p < 0.001. SAA2 had no effect on renal amyloidosis. SAA1 and SAA2 genotypes had no significant effect on SAA levels. SAA/CRP values were significantly lower in patients with the SAA1α/α genotype, compared to other SAA1 genotypes: 0.16 (0.025–1.96) versus 0.23 (0.012–28.20), p < 0.05. Conclusion. SAA1α/α genotype is one genetic factor that confers a significant risk for amyloidosis in the Turkish FMF population. Neither the SAA1 nor SAA2 genotypes had a significant effect on SAA level. (J Rheumatol 2004;31:1139–42) Key Indexing Terms: FAMILIAL MEDITERRANEAN FEVER AMYLOIDOSIS SERUM AMYLOID A POLYMORPHISM Familial Mediterranean fever (FMF) is a recessively inher- In 1997, 2 independent groups (French FMF Consortium ited disorder. The diagnosis is based on the occurrence of and International FMF Consortium) identified the gene recurrent episodes of fever and serous inflammation mani- responsible for FMF, designated MEFV, on chromosome 16 fested by sterile peritonitis, arthritis, and pleurisy. The (16p13.3)2,3. The most common MEFV mutations are disease primarily affects Sephardic Jews, Armenians, Turks, M694V, M680I, V726A, and M694I located on exon 10 and and North African Arabs. Amyloidosis of AA type, mainly E148Q located on exon 2. Genotype-phenotype correlation renal, is the major complication of FMF1. It develops over is not well established. There are unexplained ethnic differ- years and progresses to renal failure. ences in the rates of amyloidosis1,4-6. Although early data suggested that M694V mutation was a risk factor for From the Departments of Pediatrics, Pediatric Nephrology, and Medical amyloidosis, there are also patients with FMF who have Biology, and the Rheumatology Unit, Hacettepe University Faculty of Medicine, Ankara, Turkey. renal amyloidosis and do not carry the M694V homozygous 7-10 A. Bakkaloglu, MD, Professor of Pediatrics; A. Duzova, MD, Assistant genotype . Unidentified genetic and environmental Professor of Pediatrics; S. Ozen, MD, Professor of Pediatrics; N. Besbas, factors might have a protective or exacerbating effect on MD, Professor of Pediatrics; R. Topaloglu, MD, Professor of Pediatrics; renal amyloidosis. F. Ozaltin, MD, Fellow in Pediatric Nephrology, Department of Pediatrics, Pediatric Nephrology and the Rheumatology Unit; B. Balci, Serum amyloid A (SAA) protein family is known to PhD; E. Yilmaz, PhD, Associate Professor of Medical Biology, contain a number of differentially expressed apolipoproteins Department of Medical Biology. that are synthesized primarily by the liver. The concentra- Address reprint requests to Dr. A. Bakkaloglu, Department of Pediatrics, tion of acute phase SAA can increase to more than 1000- Hacettepe University Faculty of Medicine, 06100, Ankara, Turkey. 11 E-mail: [email protected] fold during inflammation . Its sensitivity was shown to be Submitted August 26, 2002; revision accepted January 6, 2004. equal or more than that of C-reactive protein (CRP) in Personal non-commercialPersonal, non-commercial use only. use The only. Journal The Journal of of RheumatologyRheumatology. Copyright Copyright© 2004. All rights © reserved. 2004. All rights reserved Bakkaloglu, et al: SAA gene polymorphisms 1139 Downloaded on September 23, 2021 from www.jrheum.org several studies; persistently high SAA levels were correlated SAA measurement. SAA levels were measured by solid phase sandwich with activity of rheumatic disease, rapid progression of ELISA method (Cytoscreen, Human SAA immunoassay kit; Biosource secondary amyloidosis, and poor outcome in patients under- International, Camarillo, CA, USA). The normal SAA level was < 10 ng/ml. Blood samples for SAA and CRP measurements were drawn at least 12,13 going certain surgical interventions . 2 weeks after an FMF attack. This period was chosen since we aimed to Acute phase isotypes of human SAA are encoded at 2 measure subclinical inflammation in these patients and not levels during an different loci, SAA1 and SAA2. SAA3 is a pseudogene14. It attack. The SAA/CRP ratio was calculated. has been suggested that AA-fibrils deposited in tissues were Analysis of polymorphisms in SAA1 and SAA2 genes. The SAA1 α, ß, and predominantly derived from SAA1α15. SAA1 and SAA2 are γ isoforms are encoded by the V52-A57, A52-V57, and A52-A57 SAA1 α serum precursors of amyloid A1 (AA1) and A2 (AA2) alleles, respectively. The SAA2 and ß isoforms are encoded by the H71 and R71 SAA2 alleles. These polymorphisms are located in the coding proteins, the principal components of the secondary amyloid region of the gene. SAA1 and SAA2 gene polymorphisms were analyzed plaques. Although prolonged high plasma levels of SAA using polymerase chain reaction-restriction fragment length polymorphism may lead to the deposition of its products, AA proteins, in (PCR-RFLP), as described23. SAA2 gene polymorphism was available in tissues, high concentrations of SAA are not sufficient to 69 patients. promote the development of amyloidosis. Recent studies Statistical analysis. Results were expressed as median (minimum- have focused on the polymorphisms of SAA as the genetic maximum) for data not showing normal distribution and as mean ± stan- 16-18 dard deviation (SD) for data showing normal distribution. Mann-Whitney background for amyloidogenesis . U and chi-squared tests were used for comparison. P values < 0.05 were Recently, Cazeneuve, et al showed in a group of considered significant. Armenian patients with FMF that the SAA1α/α genotype was associated with a 7-fold increased risk for renal amyloi- RESULTS dosis, compared with other SAA1 genotypes19. No correla- Clinical features, MEFV mutation analysis, and distribution tion with SAA levels was examined. of SAA1 and SAA2 gene polymorphisms are summarized in There is continuous subclinical inflammation in patients Table 1. Median age at onset of clinical symptoms was 3 with FMF20. Our group has previously shown that FMF (0.5–13) years, median age at diagnosis was 7 (1–16) years. patients homozygous and compound heterozygous for The mean duration of FMF was 7.5 ± 4.40 years (range MEFV mutation had higher SAA levels compared to 1–15) and duration of colchicine prophylaxis 3.50 ± 3.64 heterozygotes21. Elevated SAA levels in FMF patients can years (range 1–13). Colchicine dosage ranged from 0.5 to be secondary to either subclinical inflammation or to SAA1 genotype. It is well known that CRP correlates markedly with SAA in most inflammatory disorders, and that no study Table 1. Clinical characteristics, MEFV mutation analysis, and SAA1 and has reported the effect of a genetic factor in producing a SAA2 gene polymorphisms of 74 patients with FMF. variation in serum CRP levels. The SAA/CRP ratio can be a Features n (%) useful measure when evaluating the relation between SAA values and SAA1 genotypes in patients with continuous M/F 35/39 inflammation22. Current age, yrs median, (minimum-maximum) 11.5 (1–23) We evaluated the influence of SAA1 and SAA2 poly- Amyloidosis 8/74 (10.8) Consanguinity 20/74 (27.0) morphisms on renal amyloidosis, SAA level, and SAA/CRP Family history 34/74 (45.9) values in Turkish patients with FMF. History of appendectomy 7/74 (9.5) Clinical features MATERIALS AND METHODS Fever 70/74 (94.6) Patients. SAA1 and SAA2 gene polymorphisms and SAA levels were Abdominal pain 69/74 (93.2) determined in 74 FMF patients (39 female, 35 male; median age 11.5 yrs, Pleurisy 34/74 (45.9) range 1.0–23.0) who were homozygous or compound heterozygous for Arthritis/arthralgia 59/74 (69.7) MEFV mutation (M694V, M694I, M680I, V726A, and E148Q). MEFV mutations Homozygous or compound heterozygous patients were recruited in order to M694V/M694V 44/74 (59.5) clarify the effect of MEFV genotype on SAA level21. M694V/M680I 21/74 (28.4) The clinical data were registered on a standardized form that included M694V/V726A 9/74 (12.2) age, sex, familial consanguinity, history of the disease, age at onset of SAA1 genotypes α α symptom(s), presence of fever, abdominal pain, pleurisy, joint pain, duration / 23/74 (31.1) α of FMF disease, duration of colchicine prophylaxis, and colchicine dosage. /ß 30/74 (40.5) α γ All patients were on colchicine therapy and drug compliance was estimated / 1/74 (1.4) to be good. Informed consent was obtained from the patient or the parents. ß/ß 14/74 (18.9) ß/γ 5/74 (6.8) Mutation analysis.
Load more

Recommended publications
  • Influence of Serum Amyloid a (SAA1) And
    Influence of Serum Amyloid A (SAA1) and SAA2 Gene Polymorphisms on Renal Amyloidosis, and on SAA/ C-Reactive Protein Values in Patients with Familial Mediterranean Fever in the Turkish Population AYSIN BAKKALOGLU, ALI DUZOVA, SEZA OZEN, BANU BALCI, NESRIN BESBAS, REZAN TOPALOGLU, FATIH OZALTIN, and ENGIN YILMAZ ABSTRACT. Objective. To evaluate the effect of serum amyloid A (SAA) 1 and SAA2 gene polymorphisms on SAA levels and renal amyloidosis in Turkish patients with familial Mediterranean fever (FMF). Methods. SAA1 and SAA2 gene polymorphisms and SAA levels were determined in 74 patients with FMF (39 female, 35 male; median age 11.5 yrs, range 1.0–23.0). All patients were on colchicine therapy. SAA1 and SAA2 gene polymorphisms were analyzed using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). SAA and C-reactive protein (CRP) values were measured and SAA/CRP values were calculated. Results. The median SAA level was 75 ng/ml (range 10.2–1500). SAA1 gene polymorphisms were: α/α genotype in 23 patients (31.1%), α/ß genotype in 30 patients (40.5%), α/γ genotype in one patient (1.4 %), ß/ß genotype in 14 patients (18.9%), ß/γ genotype in 5 patients (6.8 %), and γ/γ geno- type in one patient (1.4%). Of the 23 patients who had α/α genotype for the SAA1 polymorphism, 7 patients had developed renal amyloidosis (30.4%) compared to only one patient without this geno- type (1/51; 2.0%); p < 0.001. SAA2 had no effect on renal amyloidosis. SAA1 and SAA2 genotypes had no significant effect on SAA levels.
    [Show full text]
  • Diversity and Complexity of the Mouse Saa1 and Saa2 Genes
    Exp. Anim. 63(1), 99–106, 2014 —Original— Diversity and Complexity of the Mouse Saa1 and Saa2 genes Masayuki MORI1), Geng TIAN1), Akira ISHIKAWA2), and Keiichi HIGUCHI1) 1)Department of Aging Biology, Institute of Pathogenesis and Disease Prevention, Shinshu University Graduate School of Medicine, 3–1–1 Asahi, Matsumoto, Nagano 390-8621, Japan 2)Laboratory of Animal Genetics, Division of Applied Genetics and Physiology, Graduate School of Bioagricultural Sciences, Nagoya University, Chikusa, Nagoya, Aichi 464-8601, Japan Abstract: Mouse strains show polymorphisms in the amino acid sequences of serum amyloid A 1 (SAA1) and serum amyloid A 2 (SAA2). Major laboratory mouse strains are classified based on the sequence as carrying the A haplotype (e.g., BALB/c) or B haplotype (e.g., SJL/J) of the Saa1 and Saa2 gene unit. We attempted to elucidate the diversity of the mouse Saa1 and Saa2 family genes at the nucleotide sequence level by a systematic survey of 6 inbred mouse strains from 4 Mus subspecies, including Mus musculus domesticus, Mus musculus musculus, Mus musculus castaneus, and Mus spretus. Saa1 and Saa2 genes were obtained from the mouse genome by PCR amplification, and each full-length nucleotide sequence was determined. We found that Mus musculus castaneus mice uniquely possess 2 divergent Saa1 genes linked on chromosome 7. Overall, the mouse strains had distinct composite patterns of amino acid substitutions at 9 positions in SAA1 and SAA2 isoforms. The mouse strains also had distinct composite patterns of 2 polymorphic upstream regulatory elements that influenced gene transcription in in vitro reporter assays. B haplotype mice were revealed to possess an LTR insertion in the downstream region of Saa1.
    [Show full text]
  • Human Serum Amyloid a (SAA)
    Clinical and Inflammation Research Area Human serum amyloid A (SAA) erum amyloid A recombinant SAA as well as purified endogenous apolipoprotein SAA has a tendency to aggregate and form oligomers Sfamily consists of (4-6). Presumably, the association of SAA molecules three members that in is mediated by amino acid residues located within human beings are cod- α-helix regions 1 (residues 2-8) and 3 (residues ed by different genes: 52-59) (4). SAA1, SAA2, and SAA4 (reviewed in 1-3). SAA1 The biological function of SAA and SAA2 are so-called acute phase isoforms. The biological function of SAA in inflammation is Their expression is in- unclear. It has been suggested that SAA is involved creased in response to in the recycling of cholesterol from damaged tissues. inflammation. SAA4 is It might play the role of a signaling molecule that a constitutive isoform, redirects HDL particles to activated macrophages the expression of which does not change during an and mediates the removal of stored cholesterol from acute-phase response. In addition, one more related them. Released cholesterol is then transferred to HDL gene (SAA3) has been identified, although this gene to be used again in the membranes of new cells that are is not expressed in human beings. required during acute inflammation and tissue repair (7). Besides that, published studies demonstrate Biochemical properties of SAA that recombinant SAA exhibits significant proinflammatory activity by inducing the synthesis SAA1 and SAA2 are synthesized in the liver of several cytokines and promoting chemotaxis for and secreted to the blood. When in the blood, monocytes and neutrophils in vitro (1, 8).
    [Show full text]
  • (SAA2) (NM 030754) Human Recombinant Protein Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP304977 serum amyloid A2 (SAA2) (NM_030754) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Recombinant protein of human serum amyloid A2 (SAA2), transcript variant 1 Species: Human Expression Host: HEK293T Tag: C-Myc/DDK Predicted MW: 13.3 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol Bioactivity: Cell treatment (PMID: 29757436) Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_110381 Locus ID: 6289 UniProt ID: P0DJI9 RefSeq Size: 594 Cytogenetics: 11p15.1 RefSeq ORF: 366 Synonyms: SAA; SAA1 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 serum amyloid A2 (SAA2) (NM_030754) Human Recombinant Protein – TP304977 Summary: This gene encodes a member of the serum amyloid A family of apolipoproteins. The encoded preproprotein is proteolytically processed to generate the mature protein. This protein is a major acute phase protein that is highly expressed in response to inflammation and tissue injury.
    [Show full text]
  • Comparison of Gene Expression Profiles
    [CANCER RESEARCH 62, 3939–3944, July 15, 2002] Advances in Brief Comparison of Gene Expression Profiles between Hepatitis B Virus- and Hepatitis C Virus-infected Hepatocellular Carcinoma by Oligonucleotide Microarray Data on the Basis of a Supervised Learning Method1 Norio Iizuka, Masaaki Oka,2 Hisafumi Yamada-Okabe, Naohide Mori, Takao Tamesa, Toshimasa Okada, Norikazu Takemoto, Akira Tangoku, Kenji Hamada, Hironobu Nakayama, Takanobu Miyamoto, Shunji Uchimura, and Yoshihiko Hamamoto Departments of Surgery II [N. I., M. O., N. M., T. T., T. O., N. T., A. T.] and Bioregulatory Function [N. I.], Yamaguchi University School of Medicine, Yamaguchi 755-8505; Department of Computer Science and Systems Engineering, Faculty of Engineering, Yamaguchi University, Yamaguchi 755-8611 [T. M., S. U., Y. H.]; and Department of Oncology, Nippon Roche Research Center, Kanagawa 247-8530 [H. Y-O., K. H., H. N.], Japan Abstract nisms responsible for the pathogenesis of HCC differ between HBV and HCV infections. Several studies compared gene expression be- Gene expression profiles of hepatocellular carcinomas (HCCs) associ- tween nontumorous liver and HCC and revealed gene expression ated with hepatitis B virus (HBV) and hepatitis C virus (HCV) were patterns that are rather specific to HCC (10–14). However, there is analyzed and compared. Oligonucleotide microarrays containing >6000 genes and subsequent gene selection by a supervised learning method only one study that compared gene expression patterns between HCC yielded 83 genes for which expression differed between the two types of with HBV infection (B-type HCC) and HCC with HCV infection HCCs. Expression levels of 31 of these 83 genes were increased in HBV- (C-type HCC; 14), and only a limited number of specimens were associated HCCs, and expression levels of the remaining 52 genes were analyzed.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,662,389 B2 Clark Et Al
    USOO7662389B2 (12) United States Patent (10) Patent No.: US 7,662,389 B2 Clark et al. (45) Date of Patent: Feb. 16, 2010 (54) USE OF SERUM AMYLOIDA GENE IN Cotton et al., Proc. Natl. Acad. Sci. USA 85.4397 (1988): “Reactivity DAGNOSIS AND TREATMENT OF of cytosine and thymine in single-base-pair mismatches with GLAUCOMIA AND IDENTIFICATION OF hydroxylamine and osmium tetroxide and its application to the study ANT-GLAUCOMAAGENTS of mutations'. Cotton, Mutat. Res. 285:125-144 (1993); "Current methods of muta tion detection'. (75) Inventors: Abbot F. Clark, Arlington, TX (US); Croninet al., Human Mutation 7:244-255 (1996); "Cystic Fibrosis Wan-Heng Wang, Grapevine, TX (US); Mutation Detection by Hybridization to Light-Generated DNA Loretta Graves McNatt, Hurst, TX Probe Arrays”. (US) Ermilov et al. (1993); Arkh Patol.; “Senile amyloidosis of the eye as a manifestation of senile cerebral amyloidosis' abstract with article (73) Assignee: Alcon, Inc., Hunenberg (CH) in Russian 55(6):43-45. Furlenato, CJ, and Campa A, Biochem. Biophys. Res. Commun 268:405-408 (2002), “A novel function of serum amyloid A. apotent (*) Notice: Subject to any disclaimer, the term of this stimulus for the release of tumor necrosis factor-alpha, interleukin-1 patent is extended or adjusted under 35 beta, and interleukin-8 by human blood neutrophil”. U.S.C. 154(b) by 130 days. Gasparini et al., Mol. Cell Probes 6:1-7 (1992); "Restriction site generating-polymerase chain reaction (RG-PCR) for the probeless (21) Appl. No.: 11/615.454 detection of hidden genetic variation: application to the study of some common cystic fibrosis mutations'.
    [Show full text]
  • Serum Amyloid a (SAA1) Mouse Monoclonal Antibody [Clone ID: 585] Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for AM09286PU-N Serum Amyloid A (SAA1) Mouse Monoclonal Antibody [Clone ID: 585] Product data: Product Type: Primary Antibodies Clone Name: 585 Applications: ELISA, WB Recommended Dilution: ELISA. Western Blot: Use of this SSA antibody at a concentration of 0.1-0.5 µg will allow visualization of 100 ng/lane of recombinant Human SAA. Reactivity: Human Host: Mouse Isotype: IgG2b Clonality: Monoclonal Immunogen: Highly purified recombinant Human SAA. Specificity: Reacts with natural and recombinant Human SAA. Does not show any cross-reaction with other Human Cytokines or Growth Factors tested such as IL1 beta, IL-8, MCAF, TGF beta and EGF. Formulation: 0.01 M PBS, pH 7.2 without preservatives. State: Aff - Purified State: Lyophilized purified IgG fraction. Reconstitution Method: Restore with Double distillated water to adjust the final concentration to 1.0 mg/ml. Purification: Affinity Chromatography on Protein G. Conjugation: Unconjugated Storage: Store the antibody at -20°C. Avoid repeated freezing and thawing. Stability: Shelf life: one year from despatch. Gene Name: Homo sapiens serum amyloid A1 (SAA1), transcript variant 1 Database Link: Entrez Gene 6288 Human P0DJI8 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 Serum Amyloid A (SAA1) Mouse Monoclonal Antibody [Clone ID: 585] – AM09286PU-N Background: The Serum Amyloid A (SAA) family comprises a number of differentially expressed lipoproteins, acute phase SAA1 and SAA2, the former being a major component in plasma, and constitutive SAA's (C-SAAs).
    [Show full text]
  • Recombinant Mouse Serum Amyloid A1 Catalog Number: 2948-SA
    Recombinant Mouse Serum Amyloid A1 Catalog Number: 2948-SA DESCRIPTION Source E. coli-derived mouse Serum Amyloid A1 protein Gly20-Tyr122 Accession # P05366 N-terminal Sequence Gly20 Analysis Predicted Molecular 11.8 kDa Mass SPECIFICATIONS SDS-PAGE 11 kDa, reducing conditions Activity Measured by its ability to induce TNF-α secretion by J774A.1 mouse reticulum cell sarcoma macrophage cells. The ED50 for this effect is 1.5-7.5 μg/mL. Endotoxin Level <0.10 EU per 1 μg of the protein by the LAL method. Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining. Formulation Lyophilized from a 0.2 μm filtered solution in Tris-HCl, NaCl, PEG and Imidazole. See Certificate of Analysis for details. PREPARATION AND STORAGE Reconstitution Reconstitute at 100 μg/mL in PBS. Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution. BACKGROUND Mouse Serum Amyloid A protein-1 (SAA1; previously SAA2 in mouse) is a multifunctional apolipoprotein produced by hepatocytes in response to pro-inflammatory cytokines (1 - 4). It is secreted as a 12 kDa, 103 amino acid (aa), nonglycosylated protein and circulates as part of the HDL complex (1 - 4). The SAA1 gene is one of five SAA genes in mouse (3).
    [Show full text]
  • Mouse Anti-Human Serum Amyloid a Monoclonal Antibody, Clone 4I84 (DCABH-6007) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
    Mouse Anti-Human Serum Amyloid A Monoclonal Antibody, clone 4I84 (DCABH-6007) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Specificity Recognize human SAA1. Do not recognize human SAA2, human SAA4, feline, canine, equine or bovine SAA. Immunogen Human serum amyloid A (SAA) Isotype IgG1 Source/Host Mouse Species Reactivity Human Clone 4I84 Purity Protein G purified Purification Purity≥ 95 % Conjugate Unconjugated Applications ELISA(Cap), ELISA(Det), LFIA We recommend the following for sandwich ELISA (Capture - Detection): DMAB8184 - DCABH-6007; DMAB8186 - DCABH-6007; DCABH-6007 - CABT-54364MH; CABT-54364MH - DCABH-6007 Epitope Recognizes aa 64-71 but also reacts with aa 28-38 indicating that the epitope may be partly conformational. Format Liquid Concentration Lot specific Size 1 mg Buffer 50 mM Na-citrate, pH 6.0, 0.9 % NaCI, 0.095 % NaN3 as a preservative. Preservative 0.095% sodium azide Storage Store at 2-8℃. 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved Ship Wet ice Warnings This product is for research use only and is not intended for diagnostic use. BACKGROUND Introduction Serum amyloid A (SAA) proteins are a family of apolipoproteins associated with high-density lipoprotein (HDL) in plasma. Different isoforms of SAA are expressed constitutively (constitutive SAAs) at different levels or in response to inflammatory stimuli (acute phase SAAs). These proteins are produced predominantly by the liver. The conservation of these proteins throughout invertebrates and vertebrates suggests that SAAs play a highly essential role in all animals.
    [Show full text]
  • Complete Primary Structures of Two Major Murine Serum Amyloid A
    Proc. Nati. Acad. Sci. USA Vol. 82, pp. 2915-2919, May 1985 Immunology Complete primary structures of two major murine serum amyloid A proteins deduced from cDNA sequences (amyloidosis/cDNA cloning/sequence/acute-phase protein) KEN-ICHI YAMAMOTO AND SHUNSUKE MIGITA Department of Molecular Immunology, Cancer Research Institute, Kanazawa University, Kanazawa 920, Japan Communicated by Frank W. Putnam, December 26, 1984 ABSTRACT cDNA clones encoding two major mouse mouse amyloid A protein has shown that mouse amyloid A serum amyloid A proteins, SAA1 and SAA2, were isolated from protein contains only a single type of amino-terminal amino a liver cDNA library of the lipopolysaccharide-stimulated acid sequence, which is identical with that of SAA2, indicat- BALB/c mouse, and their nucleotide sequences were deter- ing that amyloid A protein is derived predominantly from mined. The insert of the SAA2 cDNA clone contained 607 SAA2 (13). However, it is not known what structural differ- nucleotides with a 5' untranslated region of 36 nucleotides, a ences are responsible for selective deposition of SAA2 in signal peptide region corresponding to 19 amino acids, a amyloid tissues. In the present study, we have isolated two mature protein region corresponding to 103 amino acids, and cDNA clones corresponding to mouse SAA1 and SAA2 a 3' untranslated region of 202 nucleotides. The SAA1 cDINA mRNA and have determined the nucleotide sequences. A insert contained 549 nucleotides specifying a part of a signal comparison of the amino acid sequences deduced from the peptide region, a mature protein region, and a 3' untranslated cDNA sequences reveals amino acid differences in nine region.
    [Show full text]
  • SAA2 and SAA1 Amyloid a Genes, Activation of the Human Acute
    Differential Glucocorticoid Enhancement of the Cytokine-Driven Transcriptional Activation of the Human Acute Phase Serum Amyloid A Genes, SAA1 and SAA2 This information is current as of September 28, 2021. Caroline F. Thorn and Alexander S. Whitehead J Immunol 2002; 169:399-406; ; doi: 10.4049/jimmunol.169.1.399 http://www.jimmunol.org/content/169/1/399 Downloaded from References This article cites 47 articles, 20 of which you can access for free at: http://www.jimmunol.org/content/169/1/399.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2002 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Differential Glucocorticoid Enhancement of the Cytokine-Driven Transcriptional Activation of the Human Acute Phase Serum Amyloid A Genes, SAA1 and SAA2 Caroline F. Thorn and Alexander S. Whitehead1 The human acute phase serum amyloid A (A-SAA) genes, SAA1 and SAA2, have a high degree of sequence identity that extends ϳ450 bp upstream of their transcription start sites.
    [Show full text]
  • Serum Amyloid a Proteins and Their Impact on Metastasis and Immune Biology in Cancer
    cancers Review Serum Amyloid A Proteins and Their Impact on Metastasis and Immune Biology in Cancer Jesse Lee 1,2 and Gregory L. Beatty 1,2,* 1 Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA; [email protected] 2 Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA * Correspondence: [email protected]; Tel.: +1-215-746-7764 Simple Summary: The liver responds to systemic inflammation and injury in a coordinated manner, called the acute phase response. While this normal physiological response aims to restore homeostasis, malignant transformation coopts this biology to increase the risk for metastasis, immune evasion, and therapeutic resistance. In this Review, we discuss the importance of acute phase response proteins in regulating cancer biology and treatment efficacy. We also consider potential strategies to intervene on acute phase biology as an approach to improve outcomes in cancer. Abstract: Cancer triggers the systemic release of inflammatory molecules that support cancer cell metastasis and immune evasion. Notably, this biology shows striking similarity to an acute phase response that is coordinated by the liver. Consistent with this, a role for the liver in defining cancer biology is becoming increasingly appreciated. Understanding the mechanisms that link acute phase biology to metastasis and immune evasion in cancer may reveal vulnerable pathways and novel Citation: Lee, J.; Beatty, G.L. Serum therapeutic targets. Herein, we discuss a link between acute phase biology and cancer with a focus Amyloid A Proteins and Their Impact on serum amyloid A proteins and their involvement in regulating the metastatic cascade and cancer on Metastasis and Immune Biology in immunobiology.
    [Show full text]